Biological Standardization of Allergen Extracts of Pollens of Betula Pendula, Phleum Pratense and Mite Extract of Dermatophagoides Pteronyssinus
1 other identifier
interventional
68
1 country
1
Brief Summary
Allergen extracts are complex mixtures of proteins and contain varying amounts of allergenic and non-allergenic components. Many factors such as the biovariability, differences in extraction process and subsequent handling of allergens can affect the final composition, potency, and stability of allergen preparations. Genetic diversity of affected people adds another level of complexity. In order to control variability and to achieve consistency and reproducibility for optimal safety and sensitivity/specificity, it is essential to standardize the amount of allergen used in prick tests. Therefore, the system for biological standardization mainly used in Europe still is the biological calibration of in-House Reference Preparations (IHRP). The method has been adopted by the Nordic Council on Medicines as the Nordic Biological Unit, Histamine Equivalent Potency (HEP) or Skin Prick Test (SPT) value. The aim of this procedure is to estimate the biological activity of allergen extracts. The activity of an allergen extract is defined as 10,000 Diagnostic Biological Units (DBU) per ml (1 SPT per ml), when the extract provokes a specific skin reaction with a wheal of the same size as a wheal provoked by reference histamine at a concentration of 10 mg/ml, when both solutions are administrated using the same technique (prick testing) on at least 20 individuals who are clinically allergic and cutaneously reactive to the allergen concerned. The present study aims to standardize the allergen extracts of Betula pendula, Phleum pratense and Dermatophagoides pteronyssinus by using this method.
- Trial with medicinal product
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_2
Started Dec 2010
Shorter than P25 for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 25, 2010
CompletedFirst Posted
Study publicly available on registry
June 22, 2010
CompletedStudy Start
First participant enrolled
December 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2011
CompletedMay 2, 2017
April 1, 2017
4 months
May 25, 2010
April 28, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Wheal size area
The primary efficacy variable will be the wheal size area of the immediate phase reaction in mm2
15 minutes after skin prick test
Study Arms (1)
Skin Prick Test
OTHERInterventions
Skin prick test of extracts of allergens in 4 tenfold dilutions. Assessment wheal size after 15 minutes
Eligibility Criteria
You may qualify if:
- Positive clinical history with inhalant allergy to at least one of the allergen to be standardized.
- At least one positive prick test (mean wheal diameter = 3mm) when tested with already standardized extracts of the allergens under investigation.
- Positive prick test (wheal diameter =3 mm) to Histamine 10 mg/ml
- Age: 18-60 years
- Written informed consent
You may not qualify if:
- Diseases or medications, influencing the skin tests or that contradict the correct conduct and evaluation of the study.
- Pregnancy, skin irritations, drug and alcohol abuse and participation in another clinical trial within the last 30 days
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Roxall Medicina España S.Alead
- University Hospital, Zürichcollaborator
Study Sites (1)
Zentrum für klinische Forschung Clinical Trials Center, University Hospital and University Zurich
Zurich, CH-8091, Switzerland
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
01 Studienregister MasterAdmins
UniversitaetsSpital Zuerich
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 25, 2010
First Posted
June 22, 2010
Study Start
December 1, 2010
Primary Completion
April 1, 2011
Study Completion
April 1, 2011
Last Updated
May 2, 2017
Record last verified: 2017-04